Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
Sales | 91,977 | 100,803 | 72,666 | 59,850 | 53,169 |
Cost of Goods | 38,263 | 37,669 | 31,257 | N/A | N/A |
Gross Profit | 53,714 | 63,134 | 41,409 | 52,082 | 53,169 |
Operating Expenses | 109,882 | 123,326 | 117,635 | 150,008 | 81,012 |
Operating Income | -55,905 | -59,523 | -75,969 | -90,158 | -27,843 |
Interest Expense | 0 | -485 | 0 | 0 | 0 |
Other Income | 43 | 23 | 791 | 1,766 | 1,796 |
Pre-tax Income | -55,862 | -59,015 | -75,178 | -88,392 | -26,047 |
Income Tax | -1,277 | -845 | -2,757 | N/A | N/A |
Net Income Continuous | -54,585 | -58,170 | -72,421 | -60,054 | -26,047 |
Net Income | $-54,585 | $-58,170 | $-72,421 | $-60,054 | $-26,047 |
EPS Basic Total Ops | -0.46 | -0.49 | -0.62 | -0.93 | -0.46 |
EPS Basic Continuous Ops | -0.46 | -0.49 | -0.62 | -0.94 | -0.46 |
EPS Diluted Total Ops | -0.46 | -0.49 | -0.62 | -0.93 | -0.46 |
EPS Diluted Continuous Ops | -0.46 | -0.49 | -0.62 | -0.94 | -0.46 |
EBITDA(a) | $-46,281 | $-50,044 | $-66,907 | $-88,909 | $-28,003 |